Management of partial and non-responding cutaneous squamous cell carcinoma.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
20
02
2021
accepted:
18
05
2021
entrez:
2
12
2021
pubmed:
3
12
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma are the most common types of skin cancer. For patients with locally advanced and metastatic cSCC, the programmed cell death 1 (PD-1) inhibitor cemiplimab is approved for systemic treatment. Despite this revolutionary immunomodulatory therapeutic approach, tumours may fail to respond either completely or partially. In addition to the previously established local treatment with radiotherapy or systemic treatment with chemotherapy and epidermal growth factor receptor inhibitors, ongoing trials are currently focussed on re-stimulating the antitumour immune response in patients with advanced cSCC refractory to PD-1 inhibitors. In this review, ongoing and recently finished trials with different therapeutic approaches will be discussed.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
29-34Informations de copyright
© 2021 European Academy of Dermatology and Venereology.
Références
Stratigos AJ, Garbe C, Dessinioti C et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 2. Treatment. Eur J Cancer 2020; 128: 83-102.
Gellrich FF, Huning S, Beissert S et al. Medical treatment of advanced cutaneous squamous-cell carcinoma. J Eur Acad Dermatol Venereol 2019; 33(Suppl 8): 38-43.
Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 2017; 377: 2500-2501.
Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 2020; 20: 651-668.
Mooradian M, Sullivan R. What to do when anti-PD-1 therapy fails in patients with melanoma. Oncology 2019; 33: 141-148.
Administration USFaD. FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma, 2020. URL https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-cutaneous-squamous-cell-carcinoma (last accessed: 3 February 2021).
Migden MR, Rischin D, Schmults CD et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018; 379: 341-351.
Rischin D, Migden MR, Lim AM et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer 2020; 8: e000775.
Migden MR, Khushalani NI, Chang ALS et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol 2020; 21: 294-305.
Canueto J, Cardenoso E, Garcia JL et al. Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma. Br J Dermatol 2017; 176: 1279-1287.
Maubec E. Update of the management of cutaneous squamous-cell carcinoma. Acta Derm Venereol 2020; 100: adv00143.
Sugiyama E, Togashi Y, Takeuchi Y et al. Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. Sci Immunol 2020; 5: eaav3937.
Dunn L, Ho AL, Eng J et al. A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2020; 38(15_suppl): 6541
Fernandez AMA, O'Day SJ, LdlC M et al. LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004. Ann Oncol 2020; 31: S1173.
Karapetyan L, Luke JJ, Davar D. Toll-like receptor 9 agonists in cancer. Onco Targets Ther 2020; 13: 10039-10060.
Haymaker C, Andtbacka RHI, Johnson DB et al. 1083MO Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma. Ann Oncol 2020; 31: S736.
Milhem M, Zakharia Y, Davar D et al. 304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma. J Immunother Cancer 2020; 8(Suppl 3): A186-A187.
O’Day S, Perez C, Wise-Draper T et al. 423 Safety and preliminary efficacy of intratumoral cavrotolimod (AST-008), a spherical nucleic acid TLR9 agonist, in combination with pembrolizumab in patients with advanced solid tumors. J Immunother Cancer 2020; 8(Suppl 3): A257-A258.
Berraondo P, Sanmamed MF, Ochoa MC et al. Cytokines in clinical cancer immunotherapy. Br J Cancer 2019; 120: 6-15.
Algazi AP, Twitty CG, Tsai KK et al. Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma. Clin Cancer Res 2020; 26: 2827-2837.
Pfannenstiel LW, Diaz-Montero CM, Tian YF, Scharpf J, Ko JS, Gastman BR. Immune-checkpoint blockade opposes CD8(+) T-cell suppression in human and murine cancer. Cancer Immunol Res 2019; 7: 510-525.
Yeon M, Kim Y, Jung HS, Jeoung D. Histone deacetylase inhibitors to overcome resistance to targeted and immuno therapy in metastatic melanoma. Front Cell Dev Biol 2020; 8: 486.
Sun D, Li Z, Rew Y et al. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. J Med Chem 2014; 57: 1454-1472.
Wong MKK, Kelly CM, Burgess MA et al. KRT-232, a first-in-class, murine double minute 2 inhibitor (MDM2i), for TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) after anti-PD-1/L1 immunotherapy. J Clin Oncol 2020; 38(15_suppl): 10072.
Medler TR, Murugan D, Horton W et al. Complement C5a fosters squamous carcinogenesis and limits T cell response to chemotherapy. Cancer Cell 2018; 34: 561-578.e6.
Zha H, Han X, Zhu Y et al. Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade. Oncoimmunology 2017; 6: e1349587.
Thomas S, Kuncheria L, Roulstone V et al. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. J Immunother Cancer 2019; 7: 214.
Middleton MR, Aroldi F, Sacco J et al. An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: initial results from the skin cancer cohorts. J Clin Oncol 2020; 38(15_suppl): e22050.
Martin AD, Wang X, Sandberg ML et al. Re-examination of MAGE-A3 as a T-cell therapeutic target. J Immunother 2020; 44: 95-105.
Markowitz J, Brohl A, Sarnaik AA et al. Trial in progress: IFx-Hu2.0 (plasmid DNA coding for Emm55 streptococcal antigen in a cationic polymer) phase I first in human study for unresectable stage III or stage IV cutaneous melanoma, American Association for Cancer Research Annual Meeting, Washington, DC, 2020.